Gene engineering biological therapy for juvenile arthritis

Gene engineering biological therapy for juvenile arthritis

The mechanisms of action of currently used genetic engineering biological agents (GEBAs) include inhibition of cytokines, interleukins, and T cells and depletion of B cells. GEBAs were originally accessible mainly for the treatment of refractory juvenile idiopathic arthritis (JIA), including systemi...

Full description

Bibliographic Details
Main Authors:	Kh Mikhel's, Irina Petrovna Nikishina, E S Fedorov, S O Salugina, H Michels
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2011-02-01
Series:	Научно-практическая ревматология
Subjects:	genetic engineering biological agents in children juvenile arthritis biological therapy for juvenile arthritis
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1006

Similar Items

JUVENILE CHRONIC ARTHRITIS WITH EYE LESION
by: S O Salugina, et al.
Published: (2002-02-01)

THE PHENOMENON OF NEUTROPENIA DURING TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
by: M. I. Kaleda, et al.
Published: (2018-01-01)

Early juvenile arthritis – results of two-year follow up
by: S O Salugina, et al.
Published: (2009-12-01)

Frequency and diagnostic significance of anti-cyclic citrullinated peptide antibodies (ACCP) and anti-modified citrullinated vimentin antibodies (AMCV) in children with early juvenile arthritis
by: S O Salugina, et al.
Published: (2008-12-01)

CURRENT PHARMACOTHERAPY FOR SYSTEMIC JUVENILE ARTHRITIS
by: I. P. Nikishina, et al.
Published: (2015-03-01)

Retrospective analysis of the course and outcomes of juvenile arthritis in adult patients
by: Svetlana Olegovna Salugina, et al.
Published: (2010-05-01)

ULTRASOUND EXAMINATION OF THE LOCOMOTOR SYSTEM IN THE DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY IN JUVENILE ARTHRITIS
by: D. L. Alekseev, et al.
Published: (2018-01-01)

The modern approach to diagnosis of juvenile arthritides
by: S O Salugina, et al.
Published: (2008-08-01)

ETANERCEPT IN THE REAL CLINICAL PRACTICE OF TREATMENT IN PATIENTS WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS
by: Elena Spartakovna Zholobova, et al.
Published: (2013-02-01)

The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis
by: Mustafa Cakan, et al.
Published: (2020-03-01)

EVOLUTION OF SYSTEMIC JUVENILE ARTHRITIS DURING LONG-TERM FOLLOW-UP
by: Svetlana Olegovna Salugina
Published: (2012-12-01)

Juvenile idiopathic arthritis outcome and prognosis according to catamnesis evaluation
by: O V Semenova, et al.
Published: (2005-10-01)

Juvenile idiopathic arthritis – classification and methods of treatment
by: Weronika Pawłocik, et al.
Published: (2023-04-01)

MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH SYSTEMIC JUVENILE ARTHRITIS
by: S. R. Rodionovskaya, et al.
Published: (2014-06-01)

CLINICAL AND ANAMNESTICAL FEATURES OF JUVENILE CHRONIC ARTHRITIS IN THE REPUBLIC OF BURYATIA
by: L. V. Zhdanova
Published: (2013-07-01)

Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
by: Hata T, et al.
Published: (2022-08-01)

Epidemiologic investigation of juvenile rheumatoid arthritis: a ten-year study
by: Abdolreza Malek, et al.
Published: (2014-06-01)

Biologic therapy of rheumatoid arthritis
by: Damjanov Nemanja, et al.
Published: (2009-01-01)

Studying Cytokine Profile in Patients with Juvenile Rheumatoid Arthritis During Biological Therapy
by: Ya.Ye. Boyko, et al.
Published: (2014-08-01)

Current Treatments for Juvenile Idiopathic Arthritis
by: Alberto eMartini, et al.
Published: (2011-10-01)

JUVENILE ARTHRITIS IN PEDIATRIC AND ADULT RHEUMATOLOGY SERVICE: THE PROBLEM OF CONTINUITY IN THE MANAGEMENT OF PATIENTS
by: I. P. Nikishina, et al.
Published: (2018-05-01)

Risk of infection and disease activity of patients with juvenile idiopathic arthritis treated with and without biologics
by: S. Bouayad, et al.
Published: (2022-03-01)

EFFICACY AND SAFETY OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS IN CLINICAL PRACTICE
by: M. I. Kaleda, et al.
Published: (2015-04-01)

Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey
by: Sibel Balcı, et al.
Published: (2020-12-01)

First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
by: Timothy Beukelman, et al.
Published: (2022-12-01)

Update on Genetic Susceptibility and Pathogenesis in Juvenile Idiopathic Arthritis
by: Morten Herlin, et al.
Published: (2014-07-01)

Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
by: Mia Lindegaard Pedersen, et al.
Published: (2023-09-01)

Optimization of systemic juvenile arthritis treatment regimens with correction of tocilizumab intravenous administration according to data of observational retrospective study
by: M. I. Kaleda, et al.
Published: (2019-05-01)

Systemic Onset Juvenile Idiopathic Arthritis
by: Kolesnichenko A.A., et al.
Published: (2023-08-01)

JUVENILE IDIOPATHIC ARTHRITIS AND VACCINE PREVENTABLE DISEASES – A SHORT REVIEW
by: Alexis-Virgil Cochino, et al.
Published: (2017-06-01)

Early arthritis in children – first results of prospective follow up
by: S. O. Salugina, et al.
Published: (2016-05-01)

«METHOTREXATE ERA» IN CHILDREN RHEUMATOLOGY
by: S.R. Rodionovskaya, et al.
Published: (2006-01-01)

EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006-01-01)

Efficacy of rehabilitation therapy on hospital stage of treatment of patients with juvenile idiopathic arthritis
by: T A Shelepina, et al.
Published: (2008-06-01)

Renal glomerular lesions in children with juvenile rheumatoid arthritis (literature review)
by: T.P. Borysova, et al.
Published: (2021-02-01)

Juvenile Psoriatic Arthritis: Myth or Reality? An Unending Debate
by: Roberta Naddei, et al.
Published: (2023-01-01)

Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients
by: M. Romano, et al.
Published: (2014-03-01)

Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
by: A. E. Matyunova, et al.
Published: (2017-09-01)

Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data
by: Rosemary G. Peterson, et al.
Published: (2021-07-01)

Juvenile Idiopathic Arthritis
by: Kenan Barut, et al.
Published: (2017-04-01)